1 / 11

JANUS KINASE INHIBITOR MARKET

anus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis.

PrashilCMI
Télécharger la présentation

JANUS KINASE INHIBITOR MARKET

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. JANUS KINASE INHIBITOR MARKET anus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis. .

  3. Janus Kinase Inhibitor Market Drivers Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period. Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response.

  4. Janus Kinase Inhibitor Market Regional Analysis The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period. Increasing research and development projects for launch of new drugs is expected to fuel Asia Pacific janus kinase inhibitor market growth over the forecast period. For instance, Astellas Pharma Inc. — a Japan-based pharmaceutical company — conducted Phase-3 clinical trial (study completed in November 2017) of drug Peficitinib for treatment of Rheumatoid arthritis.

  5. Janus Kinase Inhibitor Market Restraints Regulatory challenges in launch of Janus kinase inhibitors is expected to hinder the market growth. For instance, in April 2017 the U.S. FDA requested Eli Lilly & Company to provide additional clinical data for the dosing of drug Olumiant to characterize safety concerns. Later in April 2018, the FDA denied company the approval for 4mg once daily dose of Olumiant due to safety concerns regarding arterial and venous thrombosis.     Janus Kinase Inhibitor Market Key Players Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc.,  Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.

  6. Janus Kinase Inhibitor Market Taxonomy • The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions.  • By Drugs • Baricitinib • Tofacitinib • Ruxolitinib • Pipeline drugs • Peficitinib

  7. By Indication • Rheumatoid arthritis • Psoriatic arthritis • Systemic lupus erythematosus • Others • By Distribution Channel • Hospital pharmacies • Retail pharmacies • Online pharmacies • By Region • North America • Latin America • Europe • Asia Pacific • Middle East • Africa

  8. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. •  What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  9. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs

  10. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  11. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related